BRIEF-Tempest Announces Agreement With Roche To Support Advancement Of Amezalpat Combination Therapy Into First-Line Hepatocellular Carcinoma Pivotal Trial

Reuters10-10

Oct 10 (Reuters) - Tempest Therapeutics Inc :

* TEMPEST ANNOUNCES AGREEMENT WITH ROCHE TO SUPPORT ADVANCEMENT OF AMEZALPAT COMBINATION THERAPY INTO FIRST-LINE HEPATOCELLULAR CARCINOMA PIVOTAL TRIAL

* TEMPEST THERAPEUTICS INC - ROCHE TO SUPPLY ATEZOLIZUMAB, TEMPEST TO LEAD STUDY

* TEMPEST THERAPEUTICS INC - RETAINS ALL RIGHTS TO AMEZALPAT

* TEMPEST THERAPEUTICS INC - PHASE 3 STUDY TO START IN Q1 2025

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2474524716?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-10 19:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2474524716","market":"us","top_or_hot":-1,"title":"BRIEF-Tempest Announces Agreement With Roche To Support Advancement Of Amezalpat Combination Therapy Into First-Line Hepatocellular Carcinoma Pivotal Trial","media":"Reuters","content":"<html><body><p>Oct 10 (Reuters) - Tempest <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc   :</p><p>   * TEMPEST ANNOUNCES AGREEMENT WITH ROCHE TO SUPPORT ADVANCEMENT OF AMEZALPAT COMBINATION THERAPY INTO FIRST-LINE HEPATOCELLULAR CARCINOMA PIVOTAL TRIAL</p><p>   * TEMPEST THERAPEUTICS INC - ROCHE TO SUPPLY ATEZOLIZUMAB, TEMPEST TO LEAD STUDY</p><p>   * TEMPEST THERAPEUTICS INC - RETAINS ALL RIGHTS TO AMEZALPAT</p><p>   * TEMPEST THERAPEUTICS INC - PHASE 3 STUDY TO START IN Q1 2025</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Tempest Announces Agreement With Roche To Support Advancement Of Amezalpat Combination Therapy Into First-Line Hepatocellular Carcinoma Pivotal Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Tempest Announces Agreement With Roche To Support Advancement Of Amezalpat Combination Therapy Into First-Line Hepatocellular Carcinoma Pivotal Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-10 19:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Oct 10 (Reuters) - Tempest Therapeutics Inc   :   * TEMPEST ANNOUNCES AGREEMENT WITH ROCHE TO SUPPORT ADVANCEMENT OF AMEZALPAT COMBINATION THERAPY INTO FIRST-LINE HEPATOCELLULAR CARCINOMA PIVOTAL ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2474524716","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2474524716","pubTimestamp":1728558438,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Oct 10  - Tempest Therapeutics Inc   :   * TEMPEST ANNOUNCES AGREEMENT WITH ROCHE TO SUPPORT ADVANCEMENT OF AMEZALPAT COMBINATION THERAPY INTO FIRST-LINE HEPATOCELLULAR CARCINOMA PIVOTAL TRIAL   * TEMPEST THERAPEUTICS INC - ROCHE TO SUPPLY ATEZOLIZUMAB, TEMPEST TO LEAD STUDY   * TEMPEST THERAPEUTICS INC - RETAINS ALL RIGHTS TO AMEZALPAT   * TEMPEST THERAPEUTICS INC - PHASE 3 STUDY TO START IN Q1 2025Source text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","TPST":"Tempest Therapeutics Inc."},"translate_title":"BRIEF-Tempest宣布与罗氏达成协议，支持将Amezalpat联合疗法推进一线肝细胞癌关键试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TPST":0.9},"content_text":"Oct 10 (Reuters) - Tempest Therapeutics Inc   :   * TEMPEST ANNOUNCES AGREEMENT WITH ROCHE TO SUPPORT ADVANCEMENT OF AMEZALPAT COMBINATION THERAPY INTO FIRST-LINE HEPATOCELLULAR CARCINOMA PIVOTAL TRIAL   * TEMPEST THERAPEUTICS INC - ROCHE TO SUPPLY ATEZOLIZUMAB, TEMPEST TO LEAD STUDY   * TEMPEST THERAPEUTICS INC - RETAINS ALL RIGHTS TO AMEZALPAT   * TEMPEST THERAPEUTICS INC - PHASE 3 STUDY TO START IN Q1 2025Source text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2474524716"}